We provide specialized Glycan-Site Conjugation services for Antibody-Drug Conjugates (ADCs), enabling pharmaceutical and biotech companies to achieve precise, site-specific drug attachment through advanced glycoengineering. By targeting the Fc glycan region of antibodies, our approach ensures highly homogeneous ADC products, with controlled Drug-to-Antibody Ratios (DAR), improved stability, and superior therapeutic performance compared to conventional conjugation methods. With expertise spanning enzymatic glycan remodeling, bioconjugation chemistry, and scalable process development, we deliver tailor-made ADC solutions that accelerate research and support regulatory compliance-all while providing a robust platform for next-generation targeted therapies.
Developing consistent and effective ADCs is one of the biggest hurdles in modern biopharmaceutical research. Traditional conjugation methods often lead to:
Heterogeneous products with variable Drug-to-Antibody Ratios (DAR).
Reduced stability and efficacy caused by random modification of amino acid residues.
Manufacturing difficulties and regulatory risks due to batch-to-batch variability.
Compromised targeting activity when conjugation interferes with antigen-binding regions.
Our Glycan-Site Conjugation service overcomes these barriers by introducing precise, reproducible, and scalable modifications at the antibody's Fc glycan region, ensuring therapeutic quality, safety, and compliance with industry standards.
We design and engineer antibody glycans to create precise and reliable conjugation sites.
We tailor linker-payload designs to meet diverse therapeutic and stability requirements.
We ensure consistent and well-defined ADCs with controlled Drug-to-Antibody Ratios (DAR).
We provide comprehensive quality control to confirm structural and functional integrity.
We guide projects from research stage to GMP-compliant large-scale production.
Site-Specific Accuracy: Ensures homogeneous ADCs with controlled DAR.
Improved Stability: Enhances therapeutic performance and reduces off-target toxicity.
Regulatory Compliance: Processes aligned with global quality and safety standards.
Scalability: Smooth transition from small-scale R&D to commercial production.
Customizable Design: Flexible linker-payload strategies tailored to your needs.
Enhanced Efficiency: Faster development timelines with robust conjugation methods.
We begin with a detailed discussion of your antibody, payload, and therapeutic goals.
This step allows us to design a customized glycan-site conjugation strategy aligned with your R&D objectives.
Using enzymatic or chemical glycoengineering, we remodel Fc glycans to create reliable conjugation sites.
This ensures site-specific accuracy without affecting antigen-binding activity.
Our experts perform controlled drug-to-antibody conjugation with optimized linkers.
The result is homogeneous ADCs with precise DAR for predictable performance and safety.
We apply advanced glycan profiling, DAR measurement, and stability testing.
This guarantees product consistency, regulatory compliance, and therapeutic reliability.
From lab-scale research to GMP-ready processes, we support smooth scale-up.
Our team ensures manufacturing robustness and readiness for commercial production.
Glycan-Site Conjugation is a site-specific method of attaching drugs to antibodies via their Fc glycans. It ensures homogeneous ADCs with controlled DAR, improving safety, stability, and therapeutic efficacy compared to random conjugation methods.
Traditional lysine or cysteine conjugation produces heterogeneous products with variable DAR. Glycan-Site Conjugation achieves higher consistency and reproducibility.
Yes, most IgG antibodies with Fc glycans can be engineered using enzymatic or chemical methods, making this approach highly versatile.
We provide glycan profiling, DAR measurement, stability testing, and bioactivity assays to guarantee product quality and regulatory compliance.
Unlock the potential of site-specific Glycan-Site Conjugation for your next-generation Antibody-Drug Conjugates. Our team combines expertise in glycoengineering, bioconjugation, and process development to deliver homogeneous, scalable, and regulatory-ready ADC solutions. Whether you are in early-stage R&D or preparing for production, we provide the precision and flexibility you need to accelerate innovation. We also offer access to a broad range of specific glycans for conjugation, including N-acetylglucosamine (GlcNAc), galactose, fucose, and sialic acid derivatives. By leveraging these tailored glycan structures, we create optimized conjugation sites that enhance stability, safety, and therapeutic performance.
Contact us today to discuss your project and discover how our Glycan-Site Conjugation services can help bring your ADC development to the next level.
